Hepatitis B Stocks List

Recent Signals

Date Stock Signal Type
2021-06-23 ABUS Crossed Above 20 DMA Bullish
2021-06-23 AIM Crossed Above 50 DMA Bullish
2021-06-23 AIM Crossed Above 20 DMA Bullish
2021-06-23 AIM Crossed Above 200 DMA Bullish
2021-06-23 ALGS MACD Bearish Centerline Cross Bearish
2021-06-23 ALGS Doji - Bullish? Reversal
2021-06-23 ARWR New 52 Week High Strength
2021-06-23 BMY 20 DMA Resistance Bearish
2021-06-23 BMY Fell Below 50 DMA Bearish
2021-06-23 BNTC NR7 Range Contraction
2021-06-23 CODX Crossed Above 50 DMA Bullish
2021-06-23 CODX Crossed Above 20 DMA Bullish
2021-06-23 CODX NR7 Range Contraction
2021-06-23 CODX Bollinger Band Squeeze Range Contraction
2021-06-23 CODX MACD Bullish Signal Line Cross Bullish
2021-06-23 DVAX Bollinger Band Squeeze Range Contraction
2021-06-23 DVAX 50 DMA Support Bullish
2021-06-23 GOVX Doji - Bullish? Reversal
2021-06-23 GOVX Bollinger Band Squeeze Range Contraction
2021-06-23 GOVX MACD Bearish Centerline Cross Bearish
2021-06-23 HOOK 1,2,3 Retracement Bearish Bearish Swing Setup
2021-06-23 HOOK Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-06-23 HOOK Narrow Range Bar Range Contraction
2021-06-23 INO Spinning Top Other
2021-06-23 IONS NR7 Range Contraction
2021-06-23 NNVC Volume Surge Other
2021-06-23 NNVC Pocket Pivot Bullish Swing Setup
2021-06-23 SBTX Crossed Above 20 DMA Bullish
2021-06-23 SBTX Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-06-23 SBTX Crossed Above 50 DMA Bullish
2021-06-23 VIR Bollinger Band Squeeze Range Contraction

Hepatitis B Stocks Recent News

Date Stock Title
Jun 23 VIR 4 Trending Health Care Stocks To Watch Right Now
Jun 23 ARWR Arrowhead posts positive data from early-stage NASH trial
Jun 23 ARWR Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress
Jun 23 INO Inovio Has 4 Sources Of Potential Value
Jun 22 HOOK Checking Back In On HOOKIPA Pharma
Jun 22 NNVC NanoViricides Review: What you Need to Know About the Company
Jun 22 BMY Sen. Wyden releases 'principles for drug pricing reform'
Jun 22 NTLA Blackstone and Intellia in agreement to launch new CAR T-cell company
Jun 22 VIR Dual-Antibody Cocktail Shows Effectiveness In COVID-19 Animal Models: Reuters
Jun 22 NTLA Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company
Jun 22 NTLA 3 Biotech Stocks With Big Catalysts in June
Jun 22 VXRT Vaxart (NASDAQ:VXRT) Is In A Good Position To Deliver On Growth Plans
Jun 21 BMY Bristol Myers' (BMY) Onureg Gets European Commission Approval
Jun 21 INO Inovio Pharmaceuticals Could See a Boost from Covid-19 Partnerships
Jun 21 VIR GSK - Vir Biotech's Sotrovimab Reduces Hospitalization, Risk Of Death In Adult COVID-19 Patients
Jun 21 VIR 30 states likely to miss President Biden’s July 4 vaccination goal, and Brazil death toll tops 500,000
Jun 21 AIM AIM Immunotech completes all treatments in early-stage ampligen study
Jun 21 AIM AIM ImmunoTech Completes All Treatments in Phase 1 Human Safety Study of Intranasal Administration of Ampligen
Jun 21 BMY Dividend Sleuthing: Bristol Myers Squibb
Jun 21 ALGS Aligos Therapeutics to Present Phase 1 Safety and Pharmacokinetic Data for STOPS™ Molecule Drug Candidate ALG-010133 and Several Nonclinical Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s Digital International Liv...

Hepatitis B is an infectious disease caused by the hepatitis B virus (HBV) that affects the liver. It can cause both acute and chronic infections. Many people have no symptoms during the initial infection. Some develop a rapid onset of sickness with vomiting, yellowish skin, tiredness, dark urine and abdominal pain. Often these symptoms last a few weeks and rarely does the initial infection result in death. It may take 30 to 180 days for symptoms to begin. In those who get infected around the time of birth 90% develop chronic hepatitis B while less than 10% of those infected after the age of five do. Most of those with chronic disease have no symptoms; however, cirrhosis and liver cancer may eventually develop. These complications result in the death of 15 to 25% of those with chronic disease.The virus is transmitted by exposure to infectious blood or body fluids. Infection around the time of birth or from contact with other people's blood during childhood is the most frequent method by which hepatitis B is acquired in areas where the disease is common. In areas where the disease is rare, intravenous drug use and sexual intercourse are the most frequent routes of infection. Other risk factors include working in healthcare, blood transfusions, dialysis, living with an infected person, travel in countries where the infection rate is high, and living in an institution. Tattooing and acupuncture led to a significant number of cases in the 1980s; however, this has become less common with improved sterility. The hepatitis B viruses cannot be spread by holding hands, sharing eating utensils, kissing, hugging, coughing, sneezing, or breastfeeding. The infection can be diagnosed 30 to 60 days after exposure. The diagnosis is usually confirmed by testing the blood for parts of the virus and for antibodies against the virus. It is one of five main hepatitis viruses: A, B, C, D, and E.The infection has been preventable by vaccination since 1982. Vaccination is recommended by the World Health Organization in the first day of life if possible. Two or three more doses are required at a later time for full effect. This vaccine works about 95% of the time. About 180 countries gave the vaccine as part of national programs as of 2006. It is also recommended that all blood be tested for hepatitis B before transfusion and condoms be used to prevent infection. During an initial infection, care is based on the symptoms that a person has. In those who develop chronic disease, antiviral medication such as tenofovir or interferon may be useful; however, these drugs are expensive. Liver transplantation is sometimes used for cirrhosis.About a third of the world population has been infected at one point in their lives, including 343 million who have chronic infections. Another 129 million new infections occurred in 2013. Over 750,000 people die of hepatitis B each year. About 300,000 of these are due to liver cancer. The disease is now only common in East Asia and sub-Saharan Africa where between 5 and 10% of adults are chronically infected. Rates in Europe and North America are less than 1%. It was originally known as "serum hepatitis". Research is looking to create foods that contain HBV vaccine. The disease may affect other great apes as well.

More about Hepatitis B
Browse All Tags